Clearmind Medicine to Acquire 51% of EV Wireless Charging Firm for $2.5M
CMND is trading near its 52-week low of $1.43 (14% above the low).
Summary
Clearmind Medicine, a clinical-stage psychedelic biotech with a $2.5M market cap, signed a non-binding LOI to acquire a 51% stake in an EV wireless charging company for $2.5M plus a $1.5M loan. The target develops wireless charging for automated parking and autonomous platforms, a sharp pivot from Clearmind's core neuroplastogen pipeline. The deal is subject to definitive agreements and due diligence, with no closing timeline given. This follows a series of highly dilutive financings and a recent reverse split; the company's cash position is tight, and the acquisition's funding source is unclear. The move into an unrelated sector raises strategic questions, but the non-binding nature and small absolute size limit immediate impact.
At the time of this announcement, CMND was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $1.43 to $524.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.